Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.44 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.44 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5544882 | 0.91 | ALDH1A1 (0.54) | CYP1A2ALDH1A1TDP1GPR35MAPK1 | |
| SCHEMBL95713 | 0.86 | CYP1A2 (0.54) | CYP1A2ALDH1A1TDP1GPR35MAPK1 | |
| SCHEMBL4942315 | 0.83 | CYP1A2 (0.58) | CYP1A2ALDH1A1TDP1GPR35MAPK1 | |
| SCHEMBL27961047 | 0.81 | CYP1A2 (0.68) | CYP1A2ALDH1A1TDP1GPR35MAPK1 | |
| SCHEMBL16389747 | 0.81 | ALDH1A1 (0.56) | CYP1A2ALDH1A1TDP1GPR35MAPK1 | |
| SCHEMBL1967926 | 0.79 | ALDH1A1 (0.53) | ALDH1A1TDP1MAPK1HPGDTSHR | |
| SCHEMBL11196835 | 0.79 | CYP1A2 (0.57) | CYP1A2ALDH1A1TDP1GPR35MAPK1 | |
| SCHEMBL601816 | 0.78 | CYP1A2 (0.60) | CYP1A2ALDH1A1TDP1GPR35MAPK1 | |
| SCHEMBL702624 | 0.78 | CYP1A2 (0.53) | CYP1A2ALDH1A1TDP1GPR35MAPK1 | |
| SCHEMBL10890268 | 0.78 | CYP1A2 (0.64) | CYP1A2ALDH1A1TDP1GPR35MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900276-A1 | BIFUNCTIONAL CHELATING AGENTS | General Electric Company (US) | 2015-08-05 | — | — | EP | claimed |
| US-20140088314-A1 | BIFUNCTIONAL CHELATING AGENTS | GENERAL ELECTRIC COMPANY (US) | 2014-03-27 | — | — | US | claimed |
| US-6316595-B1 | PNA synthesis using a base-labile amino protecting group | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-11-13 | — | — | US | claimed |
| US-6075143-A | USEFUL FOR FORMING PEPTIDE NUCLEIC ACIDS OR HYBRID OF PEPTIDE NUCLEIC ACIDS AND DEOXYNUCLEIC ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-06-13 | — | — | US | claimed |
| US-5817811-A | AMIDATION OF THE CORRESPOND ESTERIFIED AMINE COMPOUND WITH A CARBOXYLATED NUCLEOTIDE BASE | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-10-06 | — | — | US | claimed |
| EP-0672661-A1 | Substituted N-ethyl-glycinderivatives for the preparation of PNA and PNA-/DNA hybrides | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | claimed |
| US-20230374011-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | UNICHEM LABORATORIES LTD. (IN) | 2023-11-23 | — | — | US | disclosed |
| WO-2023194840-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND THEIR USE IN COVID-19 | UNICHEM LABORATORIES LIMITED (IN) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023194842-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND THEIR USE IN RHEUMATOID ARTHRITIS | UNICHEM LABORATORIES LIMITED (IN) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023194841-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND THEIR USE IN ULCERATIVE COLITIS | UNICHEM LABORATORIES LIMITED (IN) | 2023-10-12 | — | — | WO | disclosed |
| EP-4225442-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | Unichem Laboratories Ltd (IN) | 2023-08-16 | — | — | EP | disclosed |
| EP-2563847-B1 | MCR DENDRIMERS | LEIBNIZ INST FÜR PFLANZENBIOCHEMIE IPB (DE) | 2016-04-13 | — | — | EP | disclosed |
| EP-2955171-A1 | MANUFACTURE PROCESS OF N-(5-CHLOROSALICYLOYL)-8-AMINOCAPRYLIC ACID | Novartis AG (CH) | 2015-12-16 | — | — | EP | disclosed |
| EP-0672700-B1 | PNA-synthesis using an aminoprotecting group which is labile against weak acids | HOECHST AG (DE) | 1999-06-02 | — | — | EP | disclosed |
| US-5817811-A | AMIDATION OF THE CORRESPOND ESTERIFIED AMINE COMPOUND WITH A CARBOXYLATED NUCLEOTIDE BASE | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-10-06 | — | — | US | disclosed |
| EP-0761681-A2 | Process for the preparation of substituted derivatives of N-ethylglycine | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-12 | — | — | EP | disclosed |
| EP-0672661-A1 | Substituted N-ethyl-glycinderivatives for the preparation of PNA and PNA-/DNA hybrides | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
| EP-0672701-A1 | PNA-synthesis using a base labile aminoprotecting group | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
| EP-0672700-A1 | PNA-synthesis using an aminoprotecting group which is labile against weak acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
| EP-0672677-A2 | Polyamide-oligonucleotide derivatives, their production and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374011-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | CCNY, CNKSR1, CDK1 | CYP1A2 2004/4885ALDH1A1 2777/4885TDP1 3037/4885 |
| US-20140088314-A1 | BIFUNCTIONAL CHELATING AGENTS | C3AR1, C1R, C9 | CYP1A2 4561/4885ALDH1A1 4253/4885TDP1 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.